BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1899162)

  • 1. Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia.
    Champlin R; Jansen J; Ho W; Gajewski J; Nimer S; Lee K; Territo M; Winston D; Tricot G; Reichert T
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1695-6. PubMed ID: 1899162
    [No Abstract]   [Full Text] [Related]  

  • 2. Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus leukemia.
    Champlin R; Giralt S; Przepiorka D; Ho W; Lee K; Gajewski J; Nimer S; Andersson B; Wallerstein R; Ippolito C
    Prog Clin Biol Res; 1992; 377():385-94; discussion 395-8. PubMed ID: 1438435
    [No Abstract]   [Full Text] [Related]  

  • 3. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
    Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specificity of T cells invading the skin during acute graft-vs.-host disease after semiallogeneic bone marrow transplantation.
    Gaschet J; Mahé B; Milpied N; Devilder MC; Dréno B; Bignon JD; Davodeau F; Hallet MM; Bonneville M; Vié H
    J Clin Invest; 1993 Jan; 91(1):12-20. PubMed ID: 8423212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 following histo-incompatible partially T-depleted marrow grafts.
    Henslee PJ; Byers VS; Jennings CD; Marciniak E; Thompson JS; Macdonald JS; Romond EH; Messino MJ; Scannon PJ
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3004-7. PubMed ID: 2650413
    [No Abstract]   [Full Text] [Related]  

  • 7. Selective depletion of CD8 positive T-lymphocytes for prevention of graft-versus-host disease following allogeneic bone marrow transplantation.
    Champlin R; Gajewski J; Feig S; Giorgi J; Lyddane N; Lee K; Schmidt I; Winston D; Ho W; Reichert T
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2947-8. PubMed ID: 2495694
    [No Abstract]   [Full Text] [Related]  

  • 8. Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry.
    Gale RP; Horowitz MM
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():94-7. PubMed ID: 2390646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reconstitution of T cell subset repertoire diversity following multiple antigen-mismatched bone marrow transplantation.
    Friedman TM; Azhipa O; Zilberberg J; Tkachuk Y; Hsu JW; Rowley SD; Goldberg SL; Korngold R; Pecora AL; Preti RA
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1092-5. PubMed ID: 17084373
    [No Abstract]   [Full Text] [Related]  

  • 10. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
    Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
    J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
    Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
    Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of CD4 graft-versus-host activity in IL-2-treated mice.
    Sykes M; Abraham VS; Harty MW; Pearson DA
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1225-6. PubMed ID: 8442096
    [No Abstract]   [Full Text] [Related]  

  • 15. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease.
    Jiang YZ; Mavroudis DA; Dermime S; Molldrem J; Hensel NF; Barrett AJ
    Bone Marrow Transplant; 1997 May; 19(9):899-903. PubMed ID: 9156263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft-versus-leukemia reactions following bone marrow transplantation for chronic myeloid leukemia.
    Mackinnon S
    Prog Clin Biol Res; 1992; 377():113-25; discussion 126-7. PubMed ID: 1438407
    [No Abstract]   [Full Text] [Related]  

  • 18. Italian survey on allogeneic BMT for chronic myeloid leukaemia.
    Arcese W; Mandelli F; Papa G; Bacigalupo A; Van Lint MT; Lucarelli G; Galimberti P; Polchi P; Tura S; Bandini G
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():90-1. PubMed ID: 2697445
    [No Abstract]   [Full Text] [Related]  

  • 19. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is graft versus leukaemia separable from graft versus host disease?
    Jiang YZ; Macdonald D; Cullis JO; Barrett AJ
    Bone Marrow Transplant; 1991; 7 Suppl 2():26. PubMed ID: 1878702
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.